Literature DB >> 11040232

Adrenergic and reflex abnormalities in obesity-related hypertension.

G Grassi1, G Seravalle, R Dell'Oro, C Turri, G B Bolla, G Mancia.   

Abstract

Previous studies have shown that essential hypertension and obesity are both characterized by sympathetic activation coupled with a baroreflex impairment. The present study was aimed at determining the effects of the concomitant presence of the 2 above-mentioned conditions on sympathetic activity as well as on baroreflex cardiovascular control. In 14 normotensive lean subjects (aged 33. 5+/-2.2 years, body mass index 22.8+/-0.7 kg/m(2) [mean+/-SEM]), 16 normotensive obese subjects (body mass index 37.2+/-1.3 kg/m(2)), 13 lean hypertensive subjects (body mass index 24.0+/-0.8 kg/m(2)), and 16 obese hypertensive subjects (body mass index 37.5+/-1.3 kg/m(2)), all age-matched, we measured beat-to-beat arterial blood pressure (by Finapres device), heart rate (HR, by ECG), and postganglionic muscle sympathetic nerve activity (MSNA, by microneurography) at rest and during baroreceptor stimulation and deactivation induced by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. Blood pressure values were higher in lean hypertensive and obese hypertensive subjects than in normotensive lean and obese subjects. MSNA was significantly (P:<0.01) greater in obese normotensive subjects (49.1+/-3.0 bursts per 100 heart beats) and in lean hypertensive subjects (44.5+/-3.3 bursts per 100 heart beats) than in lean normotensive control subjects (32.2+/-2.5 bursts per 100 heart beats); a further increase was detectable in individuals with the concomitant presence of obesity and hypertension (62.1+/-3. 4 bursts per 100 heart beats). Furthermore, whereas in lean hypertensive subjects, only baroreflex control of HR was impaired, in obese normotensive subjects, both HR and MSNA baroreflex changes were attenuated, with a further attenuation being observed in obese hypertensive patients. Thus, the association between obesity and hypertension triggers a sympathetic activation and an impairment in baroreflex cardiovascular control that are greater in magnitude than those found in either of the above-mentioned abnormal conditions alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040232     DOI: 10.1161/01.hyp.36.4.538

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  59 in total

Review 1.  Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases.

Authors:  Priya Balasubramanian; Delton Hall; Madhan Subramanian
Journal:  Geroscience       Date:  2018-12-05       Impact factor: 7.713

Review 2.  The global epidemic of obesity: are we becoming more sympathetic?

Authors:  Kevin P Davy
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 3.  Obesity and adipokines: effects on sympathetic overactivity.

Authors:  Michael M Smith; Christopher T Minson
Journal:  J Physiol       Date:  2012-02-20       Impact factor: 5.182

Review 4.  Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure.

Authors:  Michael Doumas; Charles Faselis; Costas Tsioufis; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

5.  Impaired in vivo venous constriction in conscious obese Zucker rats with metabolic syndrome.

Authors:  Dongzhe Song; Simon R Hutchings; Catherine C Y Pang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-31       Impact factor: 3.000

6.  Abnormal sympathetic reactivity to the cold pressor test in overweight humans.

Authors:  Jeanie Park; Holly R Middlekauff; Vito M Campese
Journal:  Am J Hypertens       Date:  2012-08-16       Impact factor: 2.689

Review 7.  The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension.

Authors:  Revathy Carnagarin; Cynthia Gregory; Omar Azzam; Graham S Hillis; Carl Schultz; Gerald F Watts; Damon Bell; Vance Matthews; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-10-28       Impact factor: 5.369

Review 8.  The sympathetic nervous system alterations in human hypertension.

Authors:  Guido Grassi; Allyn Mark; Murray Esler
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

9.  Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter.

Authors:  P Valensi; S Chiheb; M Fysekidis
Journal:  Diabetologia       Date:  2013-04-13       Impact factor: 10.122

10.  Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus.

Authors:  Amy C Arnold; Hossam A Shaltout; Patricia E Gallagher; Debra I Diz
Journal:  Hypertension       Date:  2009-09-21       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.